j.chempr.2020.02.003
Article
Catalytic Decarboxylative
Radical Sulfonylation
Jiayan He,1 Guangle Chen,2 Benxiang Zhang,1 Yi Li,1 Jia-Rong Chen,3 Wen-Jing Xiao,3 Feng Liu,2,
*
SUMMARY
The Bigger Picture
Sulfones are not only important
structural motifs in
Sulfones are key structural motifs in pharmaceuticals and agrochemicals, and
their synthesis is of paramount importance in organic chemistry. While nucleo-
philic and electrophilic C(sp3)-sulfonylation are well documented, radical
C(sp3)-sulfonylation remains elusive. Herein, we report the decarboxylative
radical sulfonylation with sulfinates. With the merger of 4CzIPN (1,2,3,5-tetra-
kis(carbazol-9-yl)-4,6-dicyanobenzene) and Cu(OTf)2 as catalysts, the visible-
light-induced reaction of redox-active esters of aliphatic carboxylic acids with
organosulfinates at room temperature provides the corresponding decarboxy-
lative sulfonylation products in satisfactory yields. This redox-neutral protocol
exhibits broad substrate scope and wide functional group compatibility,
enabling the late-stage modification of complex natural products and bioactive
pharmaceuticals. The synthetic utility of the method is further demonstrated by
the improved synthesis of anti-prostate cancer drug bicalutamide. A mechanism
involving sulfonyl group transfer from Cu(II)–SO2R to alkyl radicals is proposed.
pharmaceuticals and
agrochemicals but also versatile
synthetic intermediates in organic
chemistry. Despite the significant
progress in the synthesis of
sulfones in recent years, C(sp3)-
sulfonyl bond formations remain
underdeveloped. In particular,
there have been no reports to
date of general methods for the
sulfonylation of alkyl radicals. In
this article, we introduce the
copper-catalyzed cross coupling
of sulfinates with alkyl radicals
generated via photoredox-
catalyzed decarboxylation of
redox-active esters derived from
aliphatic carboxylic acids. This
unprecedented protocol exhibits
broad substrate scope and wide
functional group compatibility,
allowing the late-stage
INTRODUCTION
Sulfones are ubiquitous in nature. They possess a wide variety of biological activities and
thus serve as important structural motifs in pharmaceuticals and agrochemicals. For
example, bicalutamide (CASODEX, AstraZeneca’s blockbuster drug) is an orally active,
nonsteroidal anti-androgen for the treatment of prostate cancer (Figure 1).1,2 Certinib
(Zykadia, Novartis) is a new drug approved by FDA (U.S. Food and Drug Administration)
in 2014 to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.3
Another example is oral drug apremilast (Otezla, Celgene), the only phosphodiesterase
4 (PDE4) inhibitor approved by FDA to treat active psoriatic arthritis and plaque psoriasis
with an annual sales of over 1.2 billion US dollars.4 In the meantime, sulfones are also ver-
satile synthetic intermediates in organic chemistry. They serve as the key building blocks
or reagents in many chemical transformations such as Julia–Lythgoe olefination5–7 and
fluoroalkylation.8 As a consequence, the synthesis of sulfones has received a consider-
able attention and significant progress has been achieved in recent years.9–13 However,
recent advances focus mainly on C(sp2)-sulfonyl bond formations such as aromatic or
vinylic sulfonylation, whereas C(sp3)-sulfonyl bond formations remain underdeveloped.
Conventional C(sp3)-sulfonylation methods include (1) nucleophilic sulfonylation of elec-
trophiles such as alkyl halides, epoxides, or Michael acceptors with organosulfinates or
thiosulfonates under basic conditions14 (Scheme 1A) and (2) electrophilic sulfonylation of
sulfonic acid derivatives such as sulfonate esters or sulfonyl chlorides with organometallic
reagents (Scheme 1B). However, the former suffers from the competing O-alkylation (to
give sulfinate esters), while the latter often leads to the corresponding sulfoxides.9 The
recently developed sulfonyl radical addition to unsaturated bonds such as alkenes pro-
vides a powerful means for C(sp3)-sulfonyl bond formations (Scheme 1C). This method
sulfonylation of complex
molecules. The synthetic utility of
the method is further
demonstrated by the improved
synthesis of anti-prostate cancer
drug bicalutamide.
Chem 6, 1–11, May 14, 2020 ª 2020 Elsevier Inc.
1